These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29625424)

  • 41. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
    Majláth Z; Toldi J; Fülöp F; Vécsei L
    Curr Med Chem; 2016; 23(9):874-83. PubMed ID: 26872942
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mavoglurant as a treatment for Parkinson's disease.
    Petrov D; Pedros I; de Lemos ML; Pallàs M; Canudas AM; Lazarowski A; Beas-Zarate C; Auladell C; Folch J; Camins A
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1165-79. PubMed ID: 24960254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Marin C; Bonastre M; Aguilar E; Jiménez A
    Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
    Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
    Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
    Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
    Mellone M; Gardoni F
    J Neural Transm (Vienna); 2018 Aug; 125(8):1225-1236. PubMed ID: 29387966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging drugs for levodopa-induced dyskinesia.
    Al Dakheel A; Beaulieu-Boire I; Fox SH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
    Conti MM; Chambers N; Bishop C
    Neurosci Biobehav Rev; 2018 Sep; 92():67-82. PubMed ID: 29782883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
    Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
    AlShimemeri S; Fox SH; Visanji NP
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):131-144. PubMed ID: 32366130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
    Choi H; Koh SH
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):83-90. PubMed ID: 29233065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
    Wang Q; Zhang W
    Front Neural Circuits; 2016; 10():105. PubMed ID: 28066191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.